Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

Innocan Pharma Corp C.INNO

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, the Company develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.

    Latest News

    Innocan Pharma Announces Closing of Debenture Unit Offering to its Largest Shareholder, Tamar...


    Innocan Pharma Announces Private Placement Offering of a Debenture Unit to its Largest...


    Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with...


    Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales...


    FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025


    A Look into the Future of Chronic Pain Management


    Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60


    Innocan Pharma Announces Private Placement of Units


    Innocan Pharma Provides its Annual "State of Research and Development" Update for 2024


    Innocan Pharma Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on...


    Innocan Pharma Reports Third Quarter 2024 Financial Results


    Investor’s corner: Solving chronic pain in dogs – A significant market opportunity


    Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential...


    Innocan Pharma to Present at the 2024 ThinkEquity Conference


    Innocan Pharma to Participate at the ThinkEquity 2024 Investor Conference in New York Also...